The receptor binding domain of MERS-CoV

the dawn of vaccine and treatment development

Nan Zhou, Yun Zhang, Jin Chun Zhang, Ling Feng, Jin Ku Bao*

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Citations (Scopus)


The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another "SARS-like" threat to the world. It has an extremely high death rate (~50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.

Original languageEnglish
Pages (from-to)143-147
Number of pages5
JournalJournal of the Formosan Medical Association
Issue number3
Publication statusPublished - Mar 2014
Externally publishedYes


  • coronavirus
  • drug design
  • Middle East
  • vaccines

Fingerprint Dive into the research topics of 'The receptor binding domain of MERS-CoV: the dawn of vaccine and treatment development'. Together they form a unique fingerprint.

  • Cite this